Compare · DXCM vs DXR
DXCM vs DXR
Side-by-side comparison of DexCom Inc. (DXCM) and Daxor Corporation (DXR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and DXR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 639.4x DXR ($44.0M).
- Over the past year, DXCM is down 14.9% and DXR is up 15.5% - DXR leads by 30.5 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 4 for DXR).
- DXCM has more recent analyst coverage (25 ratings vs 0 for DXR).
- Company
- DexCom Inc.
- Daxor Corporation
- Price
- $72.84+0.38%
- $9.78-9.07%
- Market cap
- $28.11B
- $44.0M
- 1M return
- +20.73%
- -5.28%
- 1Y return
- -14.94%
- +15.54%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2005
- News (4w)
- 26
- 4
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Daxor Corporation
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest DXR
- SEC Form DEF 14A filed by Daxor Corporation
- Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
- SEC Form NT NPORT-P filed by Daxor Corporation
- Amendment: SEC Form 40-8F-2/A filed by Daxor Corporation
- SEC Form 40-17F2 filed by Daxor Corporation
- Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis
- SEC Form 4 filed by Feldschuh Michael Richard
- Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
- Amendment: SEC Form N-CEN/A filed by Daxor Corporation
- SEC Form 4 filed by Michel Robert J